Last edition
News about "EMA regulatory application"
AbbVie Seeks EMA Approval for Subcutaneous SKYRIZI in Crohn's Disease
AbbVie submits an European Medicines Agency (EMA) application for subcutaneous SKYRIZI induction in adults with moderately to severely active Crohn’s Disease (CD), supported by phase 3 AFFIRM data.
EMA Regulatory Application | 27/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members